



C19RM Update on Awards and Pipeline

6 JULY 2021 |
Geneva, Switzerland

OVERVIEW: AWARDS AND SUBMISSIONS

(as of July 5)

C19RM Status of Awards Submissions and Pipeline



31% or US\$997 million of C19RM 2021 funding is awarded or recommended for Board Approval to 40 applicants for a portfolio average of 12% of HTM allocation.

Full Funding requests: (1) US\$229 million was awarded to 11 applicants; (2) US\$264 million recommended for Board approval of award to 4 applicants.


Fast-track Funding Requests: US\$504 million was awarded.

Demand pipeline: 57% or US\$1,842 million is submitted or under review for potential C19RM 2021 funding (**US\$21** million under Fast-track; **US\$693 million Base** and **US\$1,127 million Above Base** under Full Funding Request). The Window 4 deadline was June 30 with 51 applications received.

KPI: Notification letter KPI average of **7.4 business days**. **Full Review NL** average of **11.2 business days**.

Unfunded Demand as of 2 July is US\$567 million.


C19RM Fund Utilization projection



C19RM Award by Priority Area



Award by priority area: Investments are mainly **directed towards reinforcing COVID-19 national response**. This is expected as the initial awards are for Fast-track. Out of the fifteen Full Funding Requests **awarded or recommended for Board approval**, we continue to see prioritization of reinforcing the COVID-19 national response due to the rapid increase in cases across a number of countries.



All values in the charts are in US\$ million and rounded. Program management costs are included in Reinforce. Recent awards values may be adjusted slightly once Detailed Budgets are finalized. Values above include Fast-track awards and Full Funding Requests awarded and/ or recommended for Board approval


C19RM Award by WHO Pillars



C19RM investments are primarily **directed towards Pillar 5: National laboratories (27%), Pillar 6: Infection prevention and control (26%) and Pillar 7: Case management (33%)**

The remaining investments are mostly invested into **Pillar 9: Maintaining essential health services and systems (9%)**.

C19RM Awards by WHO Pillar




All values in the charts are in USD million and rounded. Recent awards values may be adjusted slightly once Detailed Budgets are finalized.
Values above include Fast track awards, Full funding requests awarded and/ or recommended for board approval.
Note that there was a correction in classification from Pillar 5 to Pillar 6 in this update.

C19RM Award by ACT-A Pillars



90% of \$997 million of C19RM investments are **directed towards ACT-A Gap Filling Activities** given most awards to date are via Fast-Track and Full Funding Request prioritize reinforcing the COVID-19 response. These investments are split across the **Diagnostics Pillar (\$267 million or 27%)**, the **Therapeutics Pillar (\$328 million or 33%)**, and **Health Systems Connector (\$299 million or 30%)**.

As more Full Funding Requests are reviewed and awards made, we expect that the share of complementary activities will increase.



All values in the charts are in USD million and rounded. Recent awards values may be adjusted slightly once Detailed Budgets are finalized.
Values above include Fast track awards, Full funding requests awarded and/ or recommended for board approval


C19RM Award by Health Products



Health product investments are more balanced across key Health Products

Around **60% of awards to date** are expected to use **Wambo** as the procurement channel.

C19RM Awards by type



All values in the charts are in USD million and rounded. Recent awards values may be adjusted slightly once HPMTs are finalized.

Values above include Fast track awards, Full funding requests awarded and/ or recommended for board approval

Differences in values between Global Fund defined health products are accounted for by a more limited set of products that are included under these categories.